1[1]Pfister DG,Johnson DH,Azzoli CG,et al.American society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline:updated 2003[J].J Clin Oncol,2004,22(2):330
2[2]World Health Organization.Handbook for reporting results of cancer treatment No.48[M].Geneva:World Health Organization,1979.
3[3]Wakelee H,Belanib CP.Optimizing first-line treatment options for patients with advanced NSCLC[J].Oncologist,2005,10(Suppl 3):1
4[4]Zoli W,Ricotti L,Dal Susino M,et al.Docetaxel and gemictabine activity in NSCLC cell lines and in primary cultures from human lung cancer[J].Br J Cancer,1999,81(4):609
5[5]D'Addario G,Pintilie M,Leighl NB,et al.Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer:a metaanalysis of the published literature[J].J Clin Oncol,2005,23(13):2 926
6[6]Matsui K,Hirashima T,Nitta T,et al.A phase Ⅰ/Ⅱ study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage ⅢB/Ⅳ non-small cell lung cancer[J].Jpn J Clin Oncol,2005,35(4):181
7[7]Syrigos KN,Dannos I,Dionellis G,et al.Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer:a phase Ⅱ study[J].Anticancer Res,2005,25(5):3 489
8[8]Hirsh V,Whittom R,Desjardins P,et al.Docetaxel and gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC):a phase Ⅱ multicenter trial[J].Lung Cancer,2004,46(1):113
